Syndax Pharmaceuticals vs Vir Biotechnology
Syndax Pharmaceuticals is the larger business, with $172m of revenue in fiscal 2025 against $68.6m for Vir Biotechnology (2.5 times as much). Syndax Pharmaceuticals grew faster (627.8% against -7.6%). Syndax Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -165.6% against -638.9%. Vir Biotechnology carries less debt relative to equity (0.0% against 541.5%).
| Latest fiscal year | Syndax PharmaceuticalsSNDX, 2025 | Vir BiotechnologyVIR, 2025 |
|---|---|---|
| Revenue | $172m | $68.6m |
| Revenue growth | 627.8% | -7.6% |
| Net income | −$285m | −$438m |
| Operating margin | -158.4% | -699.2% |
| Net margin | -165.6% | -638.9% |
| Return on equity | -161.8% | -45.7% |
| Free cash flow | −$323m | −$397m |
| Cash | $135m | $232m |
| Total debt | $350m | $0 |
| Debt to equity | 541.5% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 298 | 367 |
| Market value | $1.29bn | $1.91bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 10 sales | 0 buys, 35 sales |